Aldeyra Therapeutics, Inc. (ALDX)
NASDAQ: ALDX · Real-Time Price · USD
6.67
+0.41 (6.55%)
At close: Mar 28, 2025, 4:00 PM
6.63
-0.04 (-0.62%)
After-hours: Mar 28, 2025, 7:56 PM EDT

Aldeyra Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020 2019 - 2015
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2015
Selling, General & Admin
11.8913.3415.3711.289.99
Upgrade
Research & Development
48.2229.4647.3144.9424.68
Upgrade
Operating Expenses
60.1242.7962.6856.2234.67
Upgrade
Operating Income
-60.12-42.79-62.68-56.22-34.67
Upgrade
Interest Expense
-1.93-2.07-1.69-1.74-1.9
Upgrade
Interest & Investment Income
6.197.322.350.190.29
Upgrade
EBT Excluding Unusual Items
-55.85-37.54-62.02-57.78-36.28
Upgrade
Pretax Income
-55.85-37.54-62.02-57.78-38.03
Upgrade
Income Tax Expense
-----0.48
Upgrade
Net Income
-55.85-37.54-62.02-57.78-37.55
Upgrade
Net Income to Common
-55.85-37.54-62.02-57.78-37.55
Upgrade
Shares Outstanding (Basic)
5959585434
Upgrade
Shares Outstanding (Diluted)
5959585434
Upgrade
Shares Change (YoY)
0.92%0.92%8.08%59.11%25.28%
Upgrade
EPS (Basic)
-0.94-0.64-1.06-1.07-1.11
Upgrade
EPS (Diluted)
-0.94-0.64-1.06-1.07-1.11
Upgrade
Free Cash Flow
-43.21-30.33-56.65-42.56-37.49
Upgrade
Free Cash Flow Per Share
-0.73-0.51-0.97-0.79-1.10
Upgrade
EBITDA
-59.87-42.53-62.42-55.96-34.61
Upgrade
D&A For EBITDA
0.250.260.260.260.06
Upgrade
EBIT
-60.12-42.79-62.68-56.22-34.67
Upgrade
Updated Feb 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q